CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 125 filers reported holding CYTOMX THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.67 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $120,408 | -90.6% | 69,600 | -64.3% | 0.00% | -100.0% |
| Q2 2021 | $1,275,000 | +50.0% | 195,157 | +79.3% | 0.00% | 0.0% |
| Q1 2021 | $850,000 | +1534.6% | 108,849 | +1459.9% | 0.00% | – |
| Q4 2020 | $52,000 | +271.4% | 6,978 | +233.1% | 0.00% | – |
| Q3 2020 | $14,000 | -53.3% | 2,095 | -42.1% | 0.00% | – |
| Q2 2020 | $30,000 | -36.2% | 3,620 | -35.7% | 0.00% | – |
| Q4 2019 | $47,000 | +62.1% | 5,630 | +42.5% | 0.00% | – |
| Q3 2019 | $29,000 | -31.0% | 3,950 | +6.3% | 0.00% | – |
| Q2 2019 | $42,000 | +223.1% | 3,715 | +335.5% | 0.00% | – |
| Q4 2018 | $13,000 | +116.7% | 853 | +177.9% | 0.00% | – |
| Q3 2018 | $6,000 | -99.2% | 307 | -99.1% | 0.00% | -100.0% |
| Q2 2018 | $792,000 | -35.1% | 34,674 | -19.2% | 0.00% | 0.0% |
| Q1 2018 | $1,221,000 | +884.7% | 42,913 | +636.1% | 0.00% | – |
| Q4 2017 | $124,000 | – | 5,830 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 476,110 | $3,956,000 | 2.65% |
| MPM BioImpact LLC | 855,437 | $7,109,000 | 2.52% |
| Exane Asset Management | 87,876 | $730,250,000 | 0.90% |
| Congress Park Capital LLC | 94,661 | $787,000 | 0.58% |
| Perceptive Advisors | 3,253,923 | $27,040,000 | 0.54% |
| BVF INC/IL | 766,148 | $6,367,000 | 0.48% |
| RTW INVESTMENTS, LP | 1,039,593 | $8,639,000 | 0.33% |
| EcoR1 Capital, LLC | 410,000 | $3,407,000 | 0.31% |
| DAFNA Capital Management LLC | 100,000 | $831,000 | 0.28% |
| HARBOURVEST PARTNERS LLC | 79,193 | $658,000 | 0.27% |